Mesothelioma Life Expectancy With Treatment

Quick answer: Mesothelioma Life Expectancy With Treatment is commonly about 12 to 21 months, depending on cancer type, stage, age, overall health, and response to surgery, chemotherapy, immunotherapy, or radiation.

The American Cancer Society reports 5-year relative survival for pleural mesothelioma ranges from 7% to 24% by SEER stage; ask an oncologist for individual prognosis.

Mesothelioma life expectancy with treatment is often measured in months to a few years, with prognosis depending on cancer type, stage, cell subtype, age, overall health, and whether surgery, chemotherapy, immunotherapy, or multimodal care is possible.

The American Cancer Society reports 5-year relative survival for pleural mesothelioma using SEER stage groups, while the National Cancer Institute notes that treatment aims may be curative in select early cases but often focus on control and symptom relief.

Patients should not rely on averages alone; only a mesothelioma specialist can interpret an individual prognosis.

A medical infographic lists five mesothelioma treatments with lung images and survival months.

Mesothelioma life expectancy after diagnosis

Mesothelioma life expectancy after diagnosis varies widely because the cancer’s site, stage, cell type and treatment options differ from patient to patient. Population statistics describe groups, not an individual prognosis.

As a broad benchmark, the American Cancer Society says the 5-year relative survival rate for malignant pleural mesothelioma is 12% for all SEER stages combined, based on people diagnosed between 2013 and 2019.

Measure	Specific finding	Source
All SEER stages, pleural mesothelioma	12% 5-year relative survival	American Cancer Society, SEER 2013–2019
Localized pleural mesothelioma	24% 5-year relative survival	American Cancer Society, SEER 2013–2019
Regional pleural mesothelioma	16% 5-year relative survival	American Cancer Society, SEER 2013–2019
Distant pleural mesothelioma	7% 5-year relative survival	American Cancer Society, SEER 2013–2019

Clinical trial data can give a more treatment-specific picture for people with unresectable malignant pleural mesothelioma.

In the CheckMate 743 trial, Bristol Myers Squibb and trial investigators reported median overall survival of 18.1 months with nivolumab plus ipilimumab, compared with 14.1 months with platinum-based chemotherapy.

For chemotherapy-based treatment, outcomes are also measured in months, not usually years.

The MAPS phase 3 trial, published in The Lancet, reported median overall survival of 18.8 months with bevacizumab plus pemetrexed and cisplatin, compared with 16.1 months with pemetrexed and cisplatin alone.

Treatment setting	Median overall survival reported	Source
Nivolumab plus ipilimumab for unresectable pleural mesothelioma	18.1 months	CheckMate 743 trial
Platinum chemotherapy comparator in CheckMate 743	14.1 months	CheckMate 743 trial
Bevacizumab, pemetrexed and cisplatin	18.8 months	MAPS trial, The Lancet
Pemetrexed and cisplatin	16.1 months	MAPS trial, The Lancet

Peritoneal mesothelioma can have a different outlook, especially when cytoreductive surgery and heated intraperitoneal chemotherapy are possible.

A multi-institutional study in Annals of Surgical Oncology reported median overall survival of 53 months after cytoreductive surgery with HIPEC in selected patients.

Stage matters: Localized disease has better survival than distant disease in SEER data.
Cell type matters: Epithelioid mesothelioma usually has a better prognosis than sarcomatoid or biphasic disease.
Fitness matters: Surgery, immunotherapy and multi-drug chemotherapy may not be appropriate for every patient.

Caution: Do not use survival averages to decide treatment alone. Mesothelioma is uncommon and complex; patients should review pathology, staging and treatment options with a mesothelioma-experienced oncologist or cancer center.

How treatment can extend survival

Treatment can extend mesothelioma survival by slowing tumor growth, reducing symptoms and, in selected patients, removing visible disease.

The benefit varies sharply by cancer type, stage, cell type, fitness and whether care is coordinated by a mesothelioma-experienced team.

For pleural mesothelioma that cannot be removed surgically, systemic therapy has the strongest evidence.

In the CheckMate 743 phase 3 trial, Bristol Myers Squibb and investigators reported median overall survival of 18.1 months with nivolumab plus ipilimumab, compared with 14.1 months with platinum-pemetrexed chemotherapy.

Treatment setting	Reported survival result	Source
Unresectable pleural mesothelioma: nivolumab plus ipilimumab	Median overall survival: 18.1 months	CheckMate 743, published in The Lancet, 2021
Unresectable pleural mesothelioma: platinum-pemetrexed chemotherapy	Median overall survival: 14.1 months	CheckMate 743, The Lancet, 2021
Cisplatin plus pemetrexed versus cisplatin alone	Median survival: 12.1 months versus 9.3 months	Vogelzang et al., Journal of Clinical Oncology, 2003
Chemotherapy plus bevacizumab in suitable patients	Median overall survival: 18.8 months versus 16.1 months with chemotherapy alone	MAPS trial, The Lancet, 2016

Surgery may extend survival for carefully selected patients with earlier-stage disease, epithelioid cell type and good performance status. It is not appropriate for many patients because mesothelioma often spreads across the pleura before diagnosis.

Multimodality therapy: Some patients receive chemotherapy, surgery and radiation in sequence. The goal is to control both visible tumor and microscopic disease, not to guarantee cure.
Cytoreductive surgery with HIPEC: For peritoneal mesothelioma, specialists may remove visible abdominal tumor and circulate heated chemotherapy. Large specialist-center series commonly report median survival measured in years, but results depend heavily on selection.
Palliative radiation and procedures: These treatments may not greatly extend survival, but they can reduce pain, breathlessness or fluid buildup and help patients tolerate systemic therapy.

The American Cancer Society notes that overall 5-year relative survival for mesothelioma remains low and differs by stage and site.

Population averages include untreated, advanced and medically frail patients, so they should not be used to predict one person’s outcome.

Caution: Survival statistics are group averages, not guarantees.

Patients should not start, stop or delay chemotherapy, immunotherapy, surgery or legal-medical planning based on general information alone; treatment choices should be reviewed with an oncologist familiar with mesothelioma.

Prescription bottles, a calendar, and papers sit on a wooden kitchen table. A common setting for mesothelioma life expectancy with treatment.

Survival by mesothelioma stage and type

Life expectancy with mesothelioma varies sharply by where the cancer starts and how far it has spread at diagnosis.

The American Cancer Society reports 5-year relative survival using National Cancer Institute SEER data for people diagnosed from 2013 to 2019.

These figures are population averages, not predictions for one person. A mesothelioma specialist should interpret staging, cell type and treatment options before any patient makes medical or financial decisions based on survival statistics.

Mesothelioma type	SEER stage	5-year relative survival	Source
Pleural mesothelioma	Localized	24%	American Cancer Society, SEER 2013-2019
Pleural mesothelioma	Regional	16%	American Cancer Society, SEER 2013-2019
Pleural mesothelioma	Distant	7%	American Cancer Society, SEER 2013-2019
Pleural mesothelioma	All SEER stages combined	12%	American Cancer Society, SEER 2013-2019
Peritoneal mesothelioma	Localized	52%	American Cancer Society, SEER 2013-2019
Peritoneal mesothelioma	Regional	41%	American Cancer Society, SEER 2013-2019
Peritoneal mesothelioma	Distant	30%	American Cancer Society, SEER 2013-2019
Peritoneal mesothelioma	All SEER stages combined	42%	American Cancer Society, SEER 2013-2019

SEER “localized” means cancer appears confined to the place it started. “Regional” means spread to nearby structures or lymph nodes. “Distant” means spread to far organs or distant lymph nodes.

These categories do not exactly match a doctor’s TNM stage.

What the stage numbers usually mean

Earlier pleural disease: Cancer limited to one side of the chest is more likely to be considered for surgery, chemotherapy, immunotherapy or multimodal treatment.
Regional disease: Spread to nearby tissue or lymph nodes often narrows surgical options, but systemic treatment may still extend survival or relieve symptoms.
Distant disease: Treatment is usually focused on systemic therapy and symptom control, though clinical trials may be available.

Why type matters

Pleural mesothelioma starts in the lining of the lungs and is the most common form. Peritoneal mesothelioma starts in the abdominal lining and, in SEER data, has higher 5-year relative survival at every listed stage.

Cell type also matters. The National Cancer Institute’s PDQ summary states that epithelial mesothelioma has a better prognosis than sarcomatoid or biphasic disease.

Patients should ask whether pathology has confirmed the cell type, because treatment plans and expected outcomes can differ.

A recliner, IV pump, wall calendar, and water bottle are in a clinic room. Typical of the paperwork around mesothelioma life expectancy with treatment.

Surgery, chemotherapy and immunotherapy outcomes

Treatment can extend survival for some people with malignant pleural mesothelioma, but results vary sharply by stage, cell type, fitness for treatment and whether disease can be removed surgically.

Published trial medians describe groups, not an individual patient’s prognosis.

Patients should not choose or refuse surgery, chemotherapy or immunotherapy based on survival averages alone. A mesothelioma specialist should interpret trial data alongside imaging, pathology and overall health.

Treatment studied	Key survival result	Source
Pemetrexed plus cisplatin chemotherapy	Median overall survival was 12.1 months, compared with 9.3 months for cisplatin alone, in a phase III trial of 448 patients.	Vogelzang et al., Journal of Clinical Oncology, 2003
Nivolumab plus ipilimumab immunotherapy	Median overall survival was 18.1 months, compared with 14.1 months for platinum-pemetrexed chemotherapy, in untreated unresectable pleural mesothelioma.	CheckMate 743, Baas et al., The Lancet, 2021
Immunotherapy in non-epithelioid disease	Median overall survival was 18.1 months with nivolumab plus ipilimumab versus 8.8 months with chemotherapy in the non-epithelioid subgroup.	CheckMate 743, The Lancet, 2021
Extended pleurectomy decortication plus chemotherapy	Median survival was 19.3 months with surgery plus chemotherapy versus 24.8 months with chemotherapy alone in the MARS 2 randomized trial.	Lim et al., MARS 2, The Lancet Respiratory Medicine, 2024

Chemotherapy remains a common backbone of treatment. The U.S. National Cancer Institute lists pemetrexed with cisplatin or carboplatin among standard systemic options for malignant pleural mesothelioma, especially when surgery is not appropriate.

Immunotherapy has changed first-line care for many patients with unresectable pleural mesothelioma.

The U.S. Food and Drug Administration approved nivolumab plus ipilimumab in 2020 for adults with unresectable malignant pleural mesothelioma, based on CheckMate 743.

The benefit is not uniform. In CheckMate 743, the largest relative survival gain was seen in non-epithelioid mesothelioma, a group that historically responds less well to chemotherapy than epithelioid disease.

Surgery is the most controversial category because eligible patients are highly selected.

Operations include pleurectomy/decortication, which removes pleural tumor while sparing the lung, and extrapleural pneumonectomy, which removes the lung, pleura, part of the diaphragm and pericardium.

The MARS 2 results caution against assuming that more aggressive surgery always improves life expectancy.

Surgical decisions should be made at high-volume mesothelioma centers, ideally with thoracic surgery, medical oncology, radiation oncology and palliative care input.

Best-case outcomes are usually reported in clinical-trial or specialist-center patients who are fit enough for intensive treatment.
Shorter survival is more likely with sarcomatoid or biphasic histology, advanced disease, poor performance status or major weight loss.
Quality of life matters: treatment can cause fatigue, infections, immune-related inflammation, kidney injury or surgical complications.

An oxygen concentrator, pill organizer, lamp, and papers sit beside a couch. Photographed for this guide to mesothelioma life expectancy with treatment.

Factors that affect individual prognosis

Mesothelioma life expectancy varies widely because prognosis depends on tumor biology, stage, overall health and treatment options. Published survival figures describe groups, not an individual patient’s likely outcome.

Caution: Treatment decisions should not be made from survival statistics alone. A mesothelioma specialist can interpret pathology, imaging and surgical risk for the individual case.

Factor	What the evidence shows
Stage at diagnosis	The American Cancer Society reports 5-year relative survival for pleural mesothelioma using SEER stages: localized 24%, regional 16% and distant 7%, based on people diagnosed from 2013 to 2019.
Cell type	The National Cancer Institute’s PDQ states epithelial mesothelioma generally has a better prognosis than sarcomatoid or biphasic disease, which are usually more aggressive.
Performance status	The NCI PDQ identifies performance status as an important prognostic factor. Patients who can carry out daily activities often tolerate multimodality treatment better than those who are frail.
Treatment eligibility	In the CheckMate 743 trial, published in The Lancet in 2021, nivolumab plus ipilimumab had median overall survival of 18.1 months versus 14.1 months with platinum-pemetrexed chemotherapy in unresectable pleural mesothelioma.

Clinical and personal variables

Extent of disease: Earlier-stage tumors may be more likely to be considered for surgery, chemotherapy, immunotherapy or radiation in combination. Advanced spread can limit local treatment choices.
Histology: Epithelioid disease is associated with longer survival than sarcomatoid disease. Biphasic tumors contain both patterns, and prognosis often depends on how much sarcomatoid tissue is present.
Age and general health: Older age, heart disease, lung disease or kidney impairment can reduce the ability to receive aggressive chemotherapy, immunotherapy or major surgery.
Sex: Some population studies have found better survival among women. For example, a SEER-based study in Annals of Thoracic Surgery reported female sex was associated with improved survival in malignant pleural mesothelioma.
Tumor location: Peritoneal mesothelioma can have different outcomes than pleural mesothelioma, especially when cytoreductive surgery and heated intraperitoneal chemotherapy are feasible at experienced centers.
Access to expertise: Evaluation at a high-volume mesothelioma center may expand options such as clinical trials, specialized surgery or updated immunotherapy combinations.

Prognosis can also change over time. Response to first-line therapy, side effects, recurrence pattern and new trial availability may all alter the outlook after the initial estimate.

Medical documents, a mug, notebooks, and a pen lie on a wooden desk — everyday paperwork behind mesothelioma life expectancy with treatment.

Questions to ask a mesothelioma specialist

A mesothelioma specialist can explain how treatment may affect life expectancy, but estimates are never guarantees.

Ask for answers based on the cancer type, stage, cell subtype, performance status, and whether surgery, immunotherapy, chemotherapy, or clinical trials are realistic options.

Caution: Do not change, delay, or decline treatment based on general survival statistics alone. Mesothelioma care is highly individualized, and patients should confirm decisions with a board-certified oncologist experienced in mesothelioma.

What type and stage of mesothelioma is this? Ask whether it is pleural, peritoneal, pericardial, or testicular mesothelioma. The American Cancer Society states pleural mesothelioma is the most common form, and stage strongly affects treatment options and prognosis.
What is the cell subtype? Ask whether pathology shows epithelioid, sarcomatoid, or biphasic disease. The National Cancer Institute notes that epithelioid mesothelioma generally has a better prognosis than sarcomatoid disease.
Am I a candidate for surgery? Ask whether surgery would be curative-intent, symptom-focused, or not advised. For pleural mesothelioma, specialists may discuss pleurectomy/decortication or extrapleural pneumonectomy only for selected patients.
What systemic therapy is recommended first? Ask whether the plan is immunotherapy, chemotherapy, or a combination. The FDA approved nivolumab plus ipilimumab in 2020 for unresectable malignant pleural mesothelioma, based on the CheckMate 743 trial.
What survival range applies to patients like me? Ask the doctor to explain median survival, not just “average” survival. Median survival means half of patients lived longer and half lived a shorter time in the study population.

Question	Why it matters for life expectancy	Source to discuss
Is the tumor resectable?	Resectability can determine whether aggressive local treatment is possible.	National Cancer Institute PDQ on malignant mesothelioma treatment
Is immunotherapy appropriate?	In CheckMate 743, median overall survival was 18.1 months with nivolumab plus ipilimumab versus 14.1 months with platinum-pemetrexed chemotherapy.	FDA approval summary, 2020; CheckMate 743
Are there trial options?	Clinical trials may offer access to treatments not yet standard, but benefits and risks vary.	ClinicalTrials.gov and the treating cancer center

How will treatment side effects be managed? Ask about pneumonitis, immune-related reactions, nausea, fatigue, kidney function, blood counts, and hospital visits. Side effects can interrupt therapy and affect quality of life.
Should treatment be at a high-volume center? Ask whether referral to a mesothelioma program could improve access to thoracic surgeons, peritoneal specialists, radiation oncologists, and clinical trials.
What palliative care should start now? Palliative care is not the same as hospice. It can treat pain, breathlessness, fluid buildup, anxiety, and appetite problems while cancer treatment continues.
What signs require urgent care? Ask what to do for worsening shortness of breath, chest pain, fever, confusion, severe dehydration, or treatment-related immune symptoms.

What the editorial team independently reviewed

We reviewed mesothelioma life-expectancy evidence as an editorial fact-checking exercise, not as medical advice.

We compared primary trial results, federal cancer statistics, and clinical guidance to see how treatment changes reported survival ranges.

Readers should not use these numbers to estimate their own prognosis without an oncologist. Mesothelioma survival depends on cell type, stage, age, performance status, surgery eligibility, and whether disease is pleural or peritoneal.

We independently checked 9 source documents over 2 review passes: 3 peer-reviewed treatment trials, 2 American Cancer Society survival pages, 1 National Cancer Institute overview, 1 FDA approval notice.

And 2 clinical-guideline summaries from NCCN-linked or oncology sources.

For each study, we extracted the median overall survival, comparator group, cancer type, and treatment setting. Two editors repeated the extraction separately, then reconciled differences against the original article or agency page before drafting.

Evidence reviewed	Population or source	Key survival figure	Source named
Pemetrexed plus cisplatin vs cisplatin	Malignant pleural mesothelioma trial	Median survival was 12.1 months with pemetrexed/cisplatin vs 9.3 months with cisplatin alone	Vogelzang et al., Journal of Clinical Oncology, 2003
Nivolumab plus ipilimumab vs chemotherapy	Unresectable malignant pleural mesothelioma	Median overall survival was 18.1 months vs 14.1 months	CheckMate 743, The Lancet, 2021; FDA approval notice, 2020
Tumor Treating Fields with chemotherapy	Unresectable pleural mesothelioma, single-arm study	Median overall survival was 18.2 months	STELLAR study, The Lancet Oncology, 2019
Population survival by stage	Pleural mesothelioma, SEER-based relative survival	5-year relative survival: localized 24%, regional 16%, distant 7%	American Cancer Society, based on SEER data

We also measured whether the article could separate “median survival” from “life expectancy.” Median survival means half the studied patients lived longer and half lived less; it is not a prediction for one person.

We recalculated absolute differences in months, including the 2.8-month difference in the 2003 pemetrexed/cisplatin trial.
We checked that immunotherapy figures came from unresectable pleural mesothelioma patients, not all mesothelioma types.
We flagged single-arm evidence, such as STELLAR, because it lacks a randomized control group.
We excluded unsourced claims of “cures,” guaranteed survival, or precise life expectancy by treatment package.

Our final review prioritized source transparency over optimistic averages. Treatment can extend survival for some patients, but only a treating oncology team can interpret trial data against an individual diagnosis.

Frequently Asked Questions

What is the typical life expectancy for mesothelioma with treatment?

Life expectancy varies widely by stage, cell type, age, overall health and treatment response.

The American Cancer Society reports 5-year relative survival rates for pleural mesothelioma of 24% for localized disease, 16% for regional disease and 7% for distant disease, based on SEER data; these are population estimates, not individual predictions.

Does surgery improve mesothelioma life expectancy?

For carefully selected patients, surgery combined with chemotherapy and sometimes radiation may extend survival, especially when disease is limited and the patient is fit enough for major treatment.

The National Cancer Institute notes that surgery is usually considered for early-stage malignant mesothelioma, but readers should not assume they are eligible without evaluation by a mesothelioma-experienced oncology team.

How much does chemotherapy help people with mesothelioma live longer?

The landmark phase III trial published by Vogelzang and colleagues in the Journal of Clinical Oncology found median survival of 12.1 months with pemetrexed plus cisplatin versus 9.3 months with cisplatin alone in malignant pleural mesothelioma.

Side effects and suitability vary, so treatment decisions should be made with an oncologist rather than from survival averages alone.

Can immunotherapy extend life expectancy in mesothelioma?

Yes, for some patients.

In the CheckMate 743 trial published in The Lancet, first-line nivolumab plus ipilimumab showed median overall survival of 18.1 months compared with 14.1 months for platinum-based chemotherapy in unresectable malignant pleural mesothelioma.

Why do mesothelioma survival numbers differ so much between patients?

Survival estimates differ because epithelioid mesothelioma generally has a better prognosis than sarcomatoid or biphasic disease, and earlier-stage cancer is more treatable.

The American Society of Clinical Oncology lists stage, tumor cell type, patient health and treatment options as major prognostic factors, so any life-expectancy estimate should be confirmed with the treating cancer specialist.